Moderna’s chief financial officer and chief medical officer executed options and sold nearly $30 million of shares combined on Monday and Tuesday, SEC filings reviewed by CNN Business show. The sales occurred after Moderna (MRNA) excited Wall Street before markets opened Monday by announcing encouraging vaccine trial results. Moderna’s market value swelled to $29 billion — even though the company has no marketed products. After spiking to as high as $87 on Monday, Moderna’s stock price has since retreated below $70 as medical experts have debated the importance of the early findings. The securities transactions were done through automated insider trading plans, known as 10b5-1 plans, that lay out future stock trades at set prices or on set dates. Lorence Kim, Moderna’s chief financial

Read More At Article Source | Article Attribution